Jennifer Lew

Jen is the EVP & Chief Financial Officer of Annexon Biosciences, a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye. Since joining Annexon in June of 2019, Jen has played a significant role in the company’s financial strategy, including leading Annexon’s initial public offering in 2020. She previously served as Chief Financial Officer for Aduro Biotech, Inc. While at Aduro, Jen played a leadership role in the company’s preparation and execution of its initial public offering and provided financial and strategic oversight in the areas of fundraising, investor relations, strategic planning and board governance. Prior to Aduro, Jen held various roles at Dynavax Technologies Corporation, from 2004 to October 2013, most recently as Vice President of Finance and Principal Accounting Officer, where she was responsible for finance and accounting operations. Before joining Dynavax, Jen held positions as Assistant Controller and Director of Finance at QRS Corporation, a publicly held technology company, from 2000 to 2004. Jen began her career in the audit practice at Ernst & Young from 1994 to 1999. She earned a BA in Economics/Accounting and Government from Claremont McKenna College and is a Certified Public Accountant (inactive status).